Jennifer Ackil

448 total citations
5 papers, 242 citations indexed

About

Jennifer Ackil is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jennifer Ackil has authored 5 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Cancer Research. Recurrent topics in Jennifer Ackil's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Cancer Genomics and Diagnostics (2 papers). Jennifer Ackil is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Cancer Genomics and Diagnostics (2 papers). Jennifer Ackil collaborates with scholars based in United States. Jennifer Ackil's co-authors include Alice T. Shaw, Justin F. Gainor, W. Marston Linehan, Rebecca J. Nagy, Ibiayi Dagogo‐Jack, Jochen K. Lennerz, Emily Chin, Marguerite Rooney, Richard B. Lanman and Beow Y. Yeap and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Thoracic Oncology.

In The Last Decade

Jennifer Ackil

5 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Ackil United States	5	215	161	104	97	32	5	242
Rossella Messina United States	3	233 1.1×	182 1.1×	55 0.5×	75 0.8×	27 0.8×	6	269
Shanna Stopatschinskaja United States	8	171 0.8×	140 0.9×	59 0.6×	82 0.8×	24 0.8×	17	206
Masayoshi Miyawaki Japan	5	226 1.1×	180 1.1×	44 0.4×	121 1.2×	23 0.7×	7	261
Evan Rogers United States	8	188 0.9×	154 1.0×	52 0.5×	142 1.5×	27 0.8×	25	267
Florian Malchers Germany	4	220 1.0×	191 1.2×	79 0.8×	151 1.6×	44 1.4×	8	300
Christina J. Falcon United States	11	215 1.0×	183 1.1×	64 0.6×	98 1.0×	23 0.7×	22	304
Kelly Klega United States	7	158 0.7×	84 0.5×	140 1.3×	91 0.9×	44 1.4×	16	232
Marguerite Rooney United States	9	288 1.3×	218 1.4×	157 1.5×	126 1.3×	50 1.6×	11	366
Juan María Roldán‐Romero Spain	10	134 0.6×	67 0.4×	73 0.7×	160 1.6×	15 0.5×	17	247
D. Kim United States	8	323 1.5×	275 1.7×	52 0.5×	126 1.3×	31 1.0×	16	347

Countries citing papers authored by Jennifer Ackil

Since Specialization

Citations

This map shows the geographic impact of Jennifer Ackil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Ackil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Ackil more than expected).

Fields of papers citing papers by Jennifer Ackil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Ackil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Ackil. The network helps show where Jennifer Ackil may publish in the future.

Co-authorship network of co-authors of Jennifer Ackil

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Ackil. A scholar is included among the top collaborators of Jennifer Ackil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Ackil. Jennifer Ackil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Dagogo‐Jack, Ibiayi, Geoffrey R. Oxnard, Justin F. Gainor, et al.. (2020). A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.. Journal of Clinical Oncology. 38(15_suppl). 9595–9595. 6 indexed citations

2.

Dagogo‐Jack, Ibiayi, Marguerite Rooney, W. Marston Linehan, et al.. (2019). Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical Cancer Research. 25(22). 6662–6670. 112 indexed citations

3.

Dagogo‐Jack, Ibiayi, Marguerite Rooney, Rebecca J. Nagy, et al.. (2019). Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. Journal of Thoracic Oncology. 14(5). 816–824. 75 indexed citations

4.

Linehan, W. Marston, Ginger Jiang, Jennifer Ackil, et al.. (2018). Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases. Journal of Thoracic Oncology. 14(4). 683–690. 39 indexed citations

5.

Piotrowska, Zofia, Stephen V. Liu, Alona Muzikansky, et al.. (2018). Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. Journal of Clinical Oncology. 36(15_suppl). e21231–e21231. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact